The Ministry of Food and Drug Safety announced on the 6th that it has approved 'Prujacla Capsules (active ingredient: Pruquintinib)', a rare drug for metastatic colorectal cancer imported by Korea Takeda Pharmaceutical.
Prujacla Capsules exhibit anticancer effects by inhibiting signal transduction mediated by vascular endothelial growth factor receptors, which play a key role in tumor angiogenesis and growth. The Ministry expects this drug to provide new treatment opportunities for patients with metastatic colorectal cancer who have had difficulty with existing therapies.
An official from the Ministry explained, "Prujacla Capsules were designated as the 20th product under the 'Global Innovative Fast Track (GIFT)' system and underwent expedited review to be quickly introduced into medical practice."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
